

**1 Real-world effectiveness of screening programs for age-related macular degeneration:
2 amended Japanese specific health checkups and augmented screening programs with
3 OCT or AI**

4

5 Running title: Practical effectiveness of AMD screening

6

7 Authors: Hiroshi Tamura,^{1,2} Yoko Akune,³ Yoshimune Hiratsuka,⁴ Ryo Kawasaki,⁵ Ai Kido,¹

8 Masahiro Miyake,¹ Rei Goto,⁶ Masakazu Yamada⁷

9

10 1. Department of Ophthalmology & Visual Sciences, Kyoto University Graduate School of
11 Medicine, Kyoto, Japan

12 2. Center for Innovative Research and Education in Data Science, Institute for Liberal Arts and
13 Sciences, Kyoto University, Kyoto, Japan

14 3. Graduate School of Health Management, Keio University, Tokyo, Japan

15 4. Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan

16 5. Artificial Intelligence Center for Medical Research and Application, Osaka University
17 Hospital, Suita, Japan

18 6. Graduate School of Business Administration, Keio University, Tokyo, Japan

19 7. Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Japan

20

21 Corresponding author: (✉) Hiroshi Tamura MD, PhD(Kyoto), MSc(Harvard).

22 Department of Ophthalmology & Visual Sciences, Kyoto University Graduate School of

23 Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, JAPAN.

24 Email: htamura@kuhp.kyoto-u.ac.jp

25 Telephone: +81-75-366-7702 Fax: +81-75-366-7710

26

27 **Word counts**

28 Abstract: 251 words Main text: 5,071 words

29 **Number of references: 59 Number of figures: 3 Number of tables: 3**

30 Online Resources: 3 tables & 2 figures

31

32 **Abstract**

33 **Purpose:** To investigate the effectiveness of screening and subsequent intervention for age-
34 related macular degeneration (AMD) in Japan.

35 **Study Design:** Best-case-scenario analysis using a Markov model

36 **Methods:** The clinical effectiveness and cost-effectiveness of screening for AMD were
37 assessed by calculating the reduction proportion of blindness and incremental cost-effectiveness
38 ratio (ICER). The Markov model simulation began at the age of 40 years and ended at the age
39 of 90. The first-eye and second-eye combined model assumed annual state-transition
40 probabilities in the development and treatment of AMD. Data on prevalence, morbidity,
41 transition probability, utility value, and treatment costs were obtained from previously
42 published reports. Sensitivity analysis (SA) was performed to assess the influence of the
43 parameters.

44 **Results:** In the base-case analysis, screening for AMD every five years, beginning at age 40
45 until age 74, reflecting the current Japanese legal “Specific Health Checkups” showed a
46 decrease of 40.7% in the total number of blind patients. The screening program reduced the
47 number of blind people more than did the additional AREDS/AREDS2 formula supplement
48 intake. However, the ICER of screening versus no screening was 9,846,411 JPY/QALY with
49 supplemental costs and 6,364,545 JPY/QALY without supplemental costs, which were beyond

50 what people were willing to pay in Japan. SA revealed that neither OCT nor AI improved ICER,
51 and screening could be both clinically effective and cost-effective if started early and conducted
52 frequently.

53 **Conclusions:** Ophthalmologic screening for AMD is highly effective in reducing blindness but
54 is not cost-effective, as demonstrated by a Markov model based on real-world evidence from
55 Japan.

56 251/250 words

57

58 **Keywords**

59 Age-related macular degeneration, Clinical effectiveness, Cost-effectiveness analysis, Markov
60 model, Screening.

61 **Introduction**

62 Age-related macular degeneration (AMD) is the leading cause of blindness in developed
63 countries [1-5]. In Japan, AMD ranks fourth among the causes of visual impairment, and about
64 700,000 patients suffer from the disease [6]. Although no treatment for this condition has been
65 available until recently, it is now commonly treated with anti-vascular-endothelial-growth-
66 factor (anti-VEGF) intravitreal injection therapy [7, 8]. Nevertheless, the early detection of
67 AMD is still important because it leads to a better visual prognosis through the long medical
68 control period [9]. The considerable burden of disease associated with AMD, as well as the
69 public health benefits of prevention, are also highlighted [10].

70 We reported the clinical effectiveness and cost-effectiveness of screening for AMD in
71 adults for critical early detection, indicating the need for future reassessment as well as the
72 limitations at the time[11]. Subsequently, long-term data have been accumulated, mainly of
73 aflibercept, and many reports on the cost-effectiveness of treatment have been reported [9, 12-
74 16]. Although the cost-effectiveness of treatment was not consistent, the treatment has been
75 almost agreed to be cost-effective, especially after aflibercept was considered to be the
76 dominant treatment option [17, 18].

77 In contrast, there are few reports regarding comprehensive AMD management,
78 including health check-ups [19, 20]. Furthermore, there have been noticeable screening-related

79 changes, such as the increasing benefits of optical coherence tomography (OCT)[21,
80 22] ,improved accuracy of artificial intelligence (AI) for fundus images and OCT [21-24] , the
81 guidance effect on smoking cessation [25], and the refinement of the strategy for nutritional
82 supplement intake confirmed using AREDS/AREDS2 [10].

83 This article addresses the re-evaluation of the clinical effectiveness (reduction in the
84 number of blind patients) and cost-effectiveness (from a value-for-money perspective) of
85 screening and subsequent treatment of AMD in Japan using a Markov model that reflects the
86 latest data, especially long-term and real-world evidence. The following improvements, which
87 were not addressed in the previous study, were tackled with particular intensity using these
88 latest and longer-term data: to reduce the proportion of uncertain parameters; to evaluate
89 concerns regarding the long-term degradation of AMD treatment effects; to improve the
90 differing utility values when the two eyes are in different stages; and to compare the effects of
91 screenings and supplements. We also evaluated the impact of new technologies such as OCT
92 and AI for fundus image classification.

93

94 **Subjects and Methods**

95 **Markov model**

96 In this study, a model was created and analyzed using TreeAge Pro 2017 (TreeAge Software,

97 Inc., Williamstown, MA, USA) to estimate screening outcomes as described in a previous
 98 report[11]. Briefly, the model consisted of a decision tree to group adults into those receiving
 99 ophthalmologic screening (the screened group) and those not receiving screening (the non-
 100 screened group), and a Markov model of disease progression to compare two strategies: a
 101 screening strategy and a non-screening strategy. We again employed the first-eye and second-
 102 eye combined model [15], time horizon of 50 years, and direct cost model. On the other hand,
 103 we refined the model in several aspects: the model involved early AMD patients at 40 years of
 104 age as the start of the model reflecting the Japanese cohort data [26]; the natural prognostic
 105 variables updated from MARINA sham data [27] to systematic review data in 2017 [28]; the
 106 transition probabilities from early AMD to late AMD in the fellow eye was also updated from
 107 data of 2000 [29]to data of 2014 [30]; patients who did not take the AREDS/AREDS2 formula
 108 supplement were considered to be only followed-up patients not dropout patients; aflibercept
 109 was adopted instead of ranibizumab as the primary treatment; a “stable state” with only follow-
 110 up during anti-VEGF treatment was added to the Markov states. Details of these changes will
 111 also be described in the following section.

112 **Model parameters**

113 [Table 1](#) shows the parameters used in our model, including utilities, costs, and state transition
 114 probabilities. [Table 2](#) indicates the parameters of anti-VEGF therapies, such as treatment

115 frequencies and state transition probabilities. For these parameters, clinical research data on the
116 Japanese population was obtained to the extent possible; if no applicable Japanese data were
117 available, overseas data were used.

118 **Cohort (population)**

119 The model simulated a hypothetical Japanese cohort of 500,000 people aged 40 years, and the
120 simulation ran until they reached 90 years of age or died. At the beginning of the simulation,
121 early AMD patients with one-eye involvement are presumed to exist as 3.85% of the natural
122 cohort without any medical control, based on the prevalence in the Japanese population [26].
123 We used data estimated in a systematic review [28] for the natural prognostic variables.

124 **State transition**

125 The first- and second-eye combined models were again employed. The steps of disease
126 progression in each eye were categorized by the following seven Markov states ([Fig. 1](#)): normal,
127 early AMD, moderate late AMD, severe late AMD, blindness, stable, and death. Based on best-
128 corrected visual acuity (VA), the following three states were defined: moderate late AMD (VA:
129 0.5–0.9), severe late AMD (VA: 0.1–0.4), and blindness (VA: < 0.1). A stable state was newly
130 added in the current study, reflecting real-world clinical patterns. Since most AMD patients are
131 reported to be affected in only one eye [31], early AMD develops independently in each eye,
132 and the progression of AMD also occurs independently in each eye. It was assumed that the

133 cohort would develop early AMD as a prodromal stage and then moderate late AMD and later
134 stages. In each cycle, evaluated annually, each patient's disease condition was rated as
135 aggravated, maintained, or improved using transition probabilities, according to the reported
136 real-world data in Japan [32]. The probability of AMD occurring in the second eye was
137 determined using the reported accumulated incidence rates [30].

138 **Mortality rate**

139 The age-specific background mortality based on the 2017 Japan abridged life tables [33] was
140 adopted as the mortality rate.

141 **Treatments**

142 Once AMD was detected in a patient, he/she was assumed to be set under medical control with
143 the appropriate treatments principally in accordance with the Japanese clinical guidelines [34];
144 AREDS/AREDS2 formula nutritional supplement intake or follow-up in early AMD and
145 intravitreal injection of anti-VEGF both in moderate and severe late AMD. The proportion of
146 patients receiving supplements and the effect of supplements were set based on a previous
147 Japanese report [35] and an RCT conducted in the United States [36], respectively.

148 In both moderate and severe late AMD, patients were supposed to receive aflibercept
149 as an anti-VEGF injection, and the number of injections and effects were based on Japanese
150 prospective reports [14] ([Table 2](#)). For those who did not drop out of a series of treatments, the

151 number of injections per year was set at seven for the first year, three for the second year, and
152 later. However, since Nishikawa et al. reported that approximately 20% of patients did not
153 require additional injections from the 2nd year to the 4th year [14], the model assumed that 20%
154 of patients would transfer to the “stable state.” In the stable state, no additional injection with
155 aflibercept was assumed, but the aggravation probability was assumed to be the same as during
156 the treatment period.

157 Since aflibercept is the current main treatment option for AMD in Japan and also
158 considered the dominant treatment option in cost-effectiveness analyses of AMD treatment [17,
159 18], we included aflibercept treatment in the base-case analysis. Ranibizumab and
160 photodynamic therapy with verteporfin (PDT), which are currently minor treatment options,
161 were evaluated in a scenario analysis of treatment described below.

162 Among the adverse events and complications associated with the intravitreal injection
163 of anti-VEGF agents, infectious endophthalmitis is reported to be the most significant and
164 frequent [37]. The development of endophthalmitis was assumed to be a complication of the
165 aflibercept injection and to occur within 1 year of the injection. The incidence rate was
166 estimated according to a report on ranibizumab due to the absence of evidence on aflibercept
167 [38]. When blind, patients were assumed to receive no treatment but to be observed.

168 **Medical consultation without screening**

169 For members of the non-screened group, AMD was detected during a coincidental consultation
170 or spontaneous consultation due to subjective severity. In detail, our model assumed that
171 patients visited ophthalmologic clinics with presbyopia via coincidental consultation. The
172 prevalence of presbyopia in Japan is reported to be 43.8% [39] for those aged 40 years or older,
173 and our estimate of the annual rate of increase in the prevalence of presbyopia was 3%. We
174 assumed that 20% of those with presbyopia, within one year from the onset, would visit
175 ophthalmologic clinics and be diagnosed with AMD. Regarding the spontaneous consultation
176 due to subjective severity, when patients who were not under medical care became blind, all of
177 them were supposed to be seen by the ophthalmologist with spontaneous consultation due to
178 subjective severity.

179 **Medical consultation after screening**

180 In the screening group, we assumed that AMD was detected in a periodical screening program
181 in addition to coincidental consultation or spontaneous consultation due to subjective severity.
182 In the base-case analysis, the schedule of the periodical screening program was set to start at
183 age 40 and continued every five years until age 74 (age at the last screening was 70 years),
184 reflecting the current “Specific Health Checkups” legally conducted by the Japanese national
185 government. During the checkups, ophthalmic screening with fundus photography is limited to
186 people with abnormalities in blood pressure and blood tests for glucose and lipids. In this study,

187 to estimate the health-related economic effects of ophthalmic screening aimed at detecting
188 AMD in all subjects in the context of “Specific Health Checkups,” we used the same age for
189 ophthalmologic screening. The screening participation percentage was set at 50% with
190 reference to that of the “Specific Health Checkups” [40].

191 **Ophthalmologic screening program**

192 It was assumed that ophthalmologists used fundus photographs to make diagnoses for screening
193 as a reference scenario.

194 **Other outcomes**

195 The number of AMD patients, the number of blind patients, and the duration of blindness
196 (years) per person were estimated using the Markov model simulation. All of the values above
197 are cumulative values at the end of the simulation, including the patients who were supposed to
198 die during the simulation. The number of blind people was calculated by multiplying the
199 percentage of blind people in the survivors per cycle by the Japanese population estimates as
200 of 2017 [41].

201 **Clinical Effectiveness Analysis**

202 We calculated the reduction in the proportion of blind people among AMD patients by
203 comparing both screening strategies (the screened group vs. the non-screened group).

204 **Utility value**

205 The utility value for each AMD patient, or the patient's preference-based QOL, was set at 1 for
206 a healthy member of the population and at 0.97 for a patient with early AMD in both eyes.
207 Utility data were obtained using a time trade-off (TTO) method for measuring visual-acuity–
208 specific utility in patients with AMD by the categories of decimal visual acuity in the previous
209 reports: 0.7–1.0 for moderate, mean of 0.2–0.3 and 0.4–0.6 for severe, and 0.01–0.15 for
210 blindness [42]. However, when the conditions differed between the two eyes, the average of the
211 utility values for the two eyes was adopted, considering the poor health-related QOL reported
212 to be caused by the worse-seeing eye [43].

213 **Costs**

214 Our model was analyzed from the Japanese healthcare perspective. Thus, direct medical care
215 costs, including the cost of screening and nutritional supplements, were considered. The time
216 and transportation costs for the screened participants were not considered. Specialists estimated
217 the costs of screening, the detailed examination required for the definite diagnosis of AMD, and
218 treatments, based on the reimbursement rates defined in fee schedules for Japanese social health
219 insurance. All costs were in Japanese yen (JPY) and were converted into US dollars (USD)
220 (2020) using the Bank of Japan foreign exchange rates (1 US\$ = ¥ 106) [44].

221 **Cost-utility analysis**

222 Cumulative costs of screenings, treatments, and quality-adjusted life years (QALYs) were

223 calculated per person for the entire simulation period, using an annual discount rate of 2%,
224 according to the guidelines for Japanese cost-effectiveness research [45].

225 We calculated an incremental cost-effectiveness ratio (ICER) to enable comparisons
226 between the cost and the utility value for each screening strategy. ICER was calculated using
227 the following formula: $ICER = \text{incremental cost} / \text{incremental QALY Gained}$

228 The threshold of cost-effectiveness was set at 5,000,000 JPY/QALY, or 47,286
229 USD/QALY, which is the willingness to pay (WTP) in Japan [46].

230 **Sensitivity analysis**

231 One-way sensitivity analysis (one-way SA) were performed to assess the influence of each of
232 the 40 parameters on the base-case results, yielding a cost-effectiveness acceptability curve. For
233 the sensitivity analysis, the range of values for each parameter was set for the 95% confidence
234 interval (CI) or $\pm 50\%$ from the reported baseline value.

235 **Scenario analysis of screening with OCT or AI**

236 In addition to the base-case analysis, we analyzed the effectiveness of OCT and the
237 effectiveness of interpretation by AI for fundus photographs or OCT in the screening program.
238 The sensitivity and specificity of OCT interpreted by ophthalmologists are 0.970 and 0.897,
239 respectively [22], while those for fundus photographs interpreted by AI are 0.718 and 0.871
240 [23]; The sensitivity and specificity for OCT interpreted by AI were 0.982 and 0.912,

241 respectively [22]. The cost-effectiveness was also calculated, assuming a cost of 2,000 JPY to
242 add OCT and no additional cost for AI deployment.

243 **Scenario analysis of treatment**

244 Supplements are not covered by insurance, but the cost of supplements was considered in the
245 base case analysis. In the scenario analysis, two cases were analyzed: no consideration of
246 supplementation costs and no supplementation, and all patients detected as being in the
247 prodromal state were only followed up. Given that ranibizumab is currently used only for a
248 minor proportion of AMD treatments in real-world clinical practice, we also analyzed the mixed
249 pattern of aflibercept and ranibizumab in a 3:1 ratio in the scenario analysis, according to real-
250 world evidence in Japan [47]. The number of cases and the efficacy of ranibizumab treatment
251 were based on the results of the LUMINOUS [48] and HORIZON [49] studies after the first
252 and second years of treatment, respectively. Photodynamic therapy with verteporfin (PDT),
253 although minor, is still a treatment option for AMD in Japan. We also analyzed the mixed pattern
254 of combination therapy, adding PDT to the initial aflibercept treatment in the scenario analysis.

255 **Scenario analysis of smoking cessation after AMD detection**

256 Some reports have indicated suppression of AMD through smoking cessation [25] ; hence, the
257 guidance effect on smoking cessation during “the specific health check-ups” was evaluated in the
258 sensitivity analysis. The percentage of smokers in the target population was set at 22.9% [47] , the

259 incidence of early and late AMDs in smokers compared to nonsmokers were set at 1-fold and 1.5-
260 folds, respectively [50] , and the mortality rate in smokers compared to nonsmokers was set at 1.7-
261 folds[51]. Since smoking cessation guidance was reported to have a significant impact and a
262 cessation proportion of 32.6% was noted in the appropriately treated group at the smoking cessation
263 outpatient clinic [52], we assumed that a reduction of smoking among AMD patients would occur
264 at a rate between 0% and 30% after the early or late AMD detection. The cost for smoking cessation
265 guidance per person in this report was considered 40,010 JPY [52].

266 **Ophthalmologic screening schedule and cycle**

267 To determine the optimal screening program, the age at which screening was started, the age at
268 which screening was completed, and the interval between screenings were each varied within
269 their respective ranges shown in [Table 1](#) to yield the incremental cost-effectiveness ratio and
270 the reduction of the prevalence of blindness.

271 **Model validation**

272 To validate our model, we compared the reported numerical values (for the prevalence of AMD
273 and the unilaterality of AMD in persons 40 years or older) with simulated values for the non-
274 screened group.

275 **Ethics Statement**

276 All investigations in the current study adhered to the tenets of the Declaration of Helsinki.

277 Institutional Review Board approval and the requirement for individual informed consent was
278 legally waived in the Ethical Guidelines for Medical and Health Research Involving Human
279 Subjects by the Ministry of Education, Culture, Sports, Science, and Technology and the
280 Ministry of Health, Labor, and Welfare because only published data were used, no new patients
281 were enrolled, and no patient data were utilized in the research.

282

283 **Results**

284 **Clinical effectiveness analysis**

285 [Table 3](#) shows the results of clinical effectiveness in the base case. Screening interventions
286 reduced the proportion of blind patients by 40.7%. The preventive effect of blindness was
287 56.9% after controlling for age; the proportion of blind people for those aged 40 years and
288 above was 0.0014% in the screening group and 0.0033% in the non-screening group. The mean
289 cumulative duration of blindness was 7.3 years per blind person in the screening group and 9.9
290 years per person in the non-screening group, indicating that screening can also reduce the
291 duration of blindness. At the end of the simulation, 64,305 patients (46.3%) in the screening
292 group and 19,198 patients (13.8%) in the non-screening group, respectively, were detected to
293 have AMD, among the 138,822 cumulative patients with AMD.

294 **Cost-effectiveness analysis**

295 The results of the base case analysis are shown in [Table 3](#). The incremental cost of the screening
296 group was 63,303 JPY, and the incremental utility of the screening group was 0.0064 QALY.
297 Consequently, the ICER was calculated as 9,846,411 JPY/QALY.

298 **Sensitivity analysis**

299 The results for the top 10 most influential parameters among all 40 parameters in the one-way
300 SA are shown in [Fig. 2](#). The most influential parameter in the model was the utility value of the
301 blind state, and the 2nd most influential parameter was the utility value of moderate late AMD,
302 where utility values were found to have a significant impact on the model.

303 **Scenario analysis of screening with OCT or AI**

304 The screening program with fundus photography interpreted by AI and with OCT interpreted
305 by AI, as well as with OCT by an ophthalmologist, prevented 34.6%, 40.7%, and 42.0% of the
306 cases of blindness, respectively. Compared to the non-screening group, the ICERs were
307 10,524,003 JPY/QALY, 10,437,363 JPY/QALY, and 10,491,265 JPY/QALY for screening with
308 fundus photography interpreted by AI, screening with OCT interpreted by AI, and screening
309 with OCT interpreted by an ophthalmologist, respectively ([Supplementary Table 1](#)).

310 **Scenario analysis of treatment**

311 [Fig. 3](#) shows the trends in the rate of occurrence of blindness by age in the screening and non-
312 screening groups with and without supplementation. The age-adjusted blindness prevention

313 proportion was 57.9%, indicating that blindness can be prevented by the screening process even
314 without supplemental treatment. Comparing the screening and non-screening groups, excluding
315 supplement costs, the ICER significantly decreased to 6,364,545 JPY/QALY from the ICER in
316 the base case analysis. Comparing the screening and non-screening groups, assuming just
317 follow-up for the early AMD without supplementation, the ICER was 7,831,069 JPY/QALY.
318 The calculated ICERs were 10,374,159 JPY/QALY and 10,002,945 JPY/QALY in sensitivity
319 analyses of the mixed patterns of aflibercept and ranibizumab in a 3:1 ratio and adding PDT
320 pattern as an initial treatment, respectively.

321 **Scenario analysis of smoking cessation after AMD detection**

322 Simulation in smoking cessation proportion using the guidance after AMD detection did not impact
323 the clinical effectiveness, such as blindness prevention proportion, inhibition of late AMD
324 development, and delay in the late AMD development ([Supplementary Table. 2](#)). In contrast, the
325 ICERs were found to decrease with a decrease in smoking proportion. In particular, when the
326 smoking proportion decreased to 30%, a possibility of ICER falling under the WTP is implied.

327 **Ophthalmologic screening schedule and cycle**

328 The ICER and cumulative blindness prevention were calculated for 163 patterns of screening
329 programs, varying the age at the start of screening, age at the end of screening, and interval
330 between screenings within the ranges shown in Table 1. All 163 calculated screening programs

331 had positive incremental costs and positive incremental utility values compared to the non-
332 screening group. The ICER ranged from 5,368,641 JPY/QALY to 18,051,627 JPY/QALY, while
333 the cumulative blindness prevention percentage ranged from -1.2% to 81.5%. None of the
334 screening programs had an ICER of less than 5,000,000 JPY/QALY ([Supplementary Table. 3](#)).

335 The correlation between the ICER and the screening interval or the number of
336 screenings was weak. The earlier the screening program started or ended the lower the ICER
337 ([Supplementary Fig. 1](#)). On the other hand, the blindness prevention proportion was strongly
338 correlated with the cumulative number of screenings ([Supplementary Fig. 2](#)), and was not
339 affected by other factors such as age at the start of screening, screening interval, and age at the
340 end of screening.

341 **Model validation**

342 The prevalence of AMD in the simulated cohort was 1.04%, and the model's unilaterality of
343 AMD was 76.9%, which was controlled by the population aged over 40 years.

344

345 **Discussion**

346 The screening program prevented blindness caused by AMD and the cumulative incidence rate
347 of AMD. The screening program evaluated in this study reduced the number of cumulative blind
348 patients with AMD by 41%. Three times more detection and subsequent medical management

349 of AMD would have directly contributed to the prevention of blindness. The screening program
350 also shortened the duration of blindness. The deployment of the screening program is expected
351 to continue and boost the preventive effect of halving social blindness by anti-VEGF, as already
352 shown in 2012 [53].

353 While the clinical effectiveness of the ophthalmologic screening program for AMD
354 was again confirmed, its insufficient cost-effectiveness was again confirmed. The ICER in the
355 base case was calculated as 9,846,411 JPY/QALY, which is higher than the WTP, although it
356 significantly reduced from 27,486,352 JPY/QALY [11]. The ICERs were greater than the WTP
357 threshold for any of the one-way SA with 40 parameters. These results indicate that
358 ophthalmologic screening for AMD is not cost-effective. Combined with the significant
359 improvement over the previous results, it is expected to be worth assessing the cost-
360 effectiveness of the ophthalmologic screening for AMD in the near future.

361 The insufficient cost-effectiveness might be affected by the re-adoption of the first-eye
362 and second-eye combined model, as discussed previously. We also adopted the strategy of
363 lowering the utility when the binocular states were different to prevent the results from being
364 extreme, referring to a previous report. Previous studies, focusing on the cost-effectiveness of
365 treatments, have frequently used the second-eye model [9, 12-18]. The second-eye model may
366 be a possible option for cost-effectiveness research specialized in treatment; however, the first-

367 eye and second-eye combined model would be a better strategy for cost-effectiveness research
368 of long-term models with screening.

369 In order to verify the model's external validity, we compared the simulated values for
370 the non-screened group (prevalence of AMD in those aged ≥ 40 years and incidence of unilateral
371 AMD) to reported data from Japanese cohorts. The prevalence of AMD in those aged ≥ 40 years
372 in the simulated cohort was 1.04 %, which was within the range of 0.09-1.40 %, including those
373 aged ≥ 35 years and those aged ≥ 50 years [54, 31, 55, 32]. The model's unilateral AMD
374 incidence of 76.9% was comparable to the 83.5% reported in the Nagahama study [31]. The
375 model was validated and shown to adequately represent the real-world epidemiologic status.

376 Indirect costs and non-medical costs were not included in the current study according
377 to the guidelines for Japanese cost-effectiveness research [45]. Supplement intake is included
378 in evaluations in the base-case analysis, although their marginal positioning characteristics may
379 cause some discussions. Supplements are widely used in actual clinical practice as
380 recommended in the guidelines [34], but they are not covered by public health insurance. Given
381 that it is not necessary to include the cost of supplements in the cost-effectiveness research from
382 the Japanese public health care perspective, we added a cost-effectiveness analysis excluding
383 the cost of supplements. The ICER without the cost of supplements was significantly lower
384 than the ICER for the base case analysis. The screening program prevented blindness more than

385 the additional intake of supplements did.

386 Considering that AREDS/AREDS2 formula supplements are not a burden on the
387 society, the option of finding early AMD proactively with screening to increase clinical
388 effectiveness and cost-effectiveness is becoming more realistic. On the other hand, it may be
389 difficult to ensure continuous life-long usage of nutritional supplements due to the high burden
390 on the patients themselves and their motivation to continue [35]. Assuming only follow-up for
391 early AMD without supplement treatment, the effect of screening on blindness was higher even
392 without supplemental treatment, although cost-effective issues remain. Regardless of
393 supplement discussion, screening could be recommended.

394 The ICER and the prevention of blindness for a scenario analysis of a 3:1 ratio of
395 aflibercept and ranibizumab, reflecting current clinical practice [47], was 10,374,159
396 JPY/QALY and 28.0%, respectively. Although ranibizumab is expected to improve the visual
397 acuity to about the same degree as aflibercept, higher deterioration rates of ranibizumab resulted
398 in more blindness than aflibercept [17] even when detected earlier in the screening program.
399 The equivalent ICER to the base case analysis may be due to the assumption that only the
400 follow-up cost was counted in the blind state. The scenario analysis including PDT in the
401 treatment also did not differ significantly from the base-case analysis, or at least did not show
402 a trend towards improving efficacy.

403 The necessity of the study on the economic impact of AI is discussed in a systematic
404 review [56]. We performed a cost-effectiveness analysis of AI, assuming no additional cost of
405 examination when the fundus photographs or OCT were interpreted by AI, and we reported that
406 the ICER for the screening group compared with that of the non-screening group was almost
407 equivalent to the base-case analysis. The cost of screening with AI is difficult to estimate; it
408 might be higher because of the cost of equipment and analytical software than the base-case
409 analysis; this might be lower because of the reduced cost of personal than the base-case analysis.
410 However, our results confirmed that the implementation of AI did not impair clinical
411 effectiveness. Cost effectiveness can be expected to improve depending on progress in the
412 implementation costs of AI.

413 In the OCT analysis, both clinical-effectiveness and cost-effectiveness were
414 comparable to those of the base-case analysis. Although OCT increases the accuracy of
415 screening [21, 22], the degree of improvement did not extend to a recommendation for
416 additional screening, as patients were more likely to be medically managed at the early AMD
417 stage in periodically repeated screening.

418 The 163 patterns of SA results with 40 varying parameters cover a wide range,
419 indicating that the choice of the program has a significant impact on blindness prevention and
420 cost-effectiveness. Younger age at the start and end of screening resulted in lower ICERs,

421 whereas blindness prevention proportion was highly correlated with the cumulative number of
422 screenings and was not affected by other factors. This indicates that screening can be both
423 clinically effective and cost-effective if it is started early and conducted frequently. Although
424 some of the simulated programs in SA were more cost-effective than the base case, it would be
425 practical and realistic to focus on adding a simultaneous ophthalmologic screening program to
426 “the specific health check-ups” as a base case [57].

427 In the current study, the cost effectiveness of screening for AMD was also beyond the
428 WTP; however, the ICER was significantly improved compared to that in the previous report
429 [11]. If the high efficacy of the new drugs is confirmed, costs are reduced, and the efficiency of
430 screening, including AI, is improved, it will be realistic to expect that cost effectiveness of the
431 screening of AMD alone will be lower than the WTP in future re-assessments. In particular, it
432 may be effective to consider customized implementations, such as increasing the weight of the
433 screening program for younger people in “the specific health check-ups”, since the cost
434 effectiveness of screening was better when it was started early and conducted frequently.
435 Furthermore, we would like to realize an integrated model by combining models for other major
436 diseases such as cataract, diabetic retinopathy, glaucoma, and degenerative myopia, which are
437 being investigated separately.

438 Continued smoking cessation was also considered as one of the important factors to

439 achieve cost-effectiveness in the AMD screening program. In this study, we combined several broad
440 assumptions but did not obtain robust results. However, it was hypothesized that the ICER would
441 be under the WTP, especially if a relatively higher retention rate than the current situation of 30%
442 smoking cessation could be achieved. In general, the effect of smoking cessation measures on health
443 care costs was reported to have a decreasing effect in the short term, but an increasing effect in the
444 long term [58] [59] . Although improvement in the effectiveness of smoking cessation following
445 smoking cessation guidance is expected, it is necessary to evaluate the cost-effectiveness of
446 AMD screening carefully, keeping these general principles in mind.

447 We implemented the current study with long-term real-world data, mainly of
448 aflibercept, from the perspective of comprehensive management for AMD. As a result, we have
449 improved many of the problematic issues of the previous study. Nevertheless, several
450 limitations should be noted. First, speculation on parameters lacking in evidence is needed, such
451 as utility when the state differs in two eyes, the proportion of patients dropping out of treatment,
452 the effectiveness and intake rates of supplements, and rates and costs of detailed examinations
453 or subsequent periodic examination. Regarding these parameters, relatively wider sensitive
454 analyses were used to compensate for the lack of evidence. We were, fortunately, able to
455 confirm that the base-case analysis was not far out of the focus because the impact of these
456 parameters on the results was limited. There still remains, however, a need to reevaluate the

457 results with more accurate parameters that will be reported in the future. Second, we could not
458 include promising drugs such as brolucizumab in the model due to the lack of reported evidence
459 since they are still in the early stages of real practice. Finally, we could not set the cost change
460 when implementing AI and had to assume no change in cost. Expectations are increasing for
461 the implementation of AI to both reduce costs and maintain high accuracy. However, due to the
462 lack of sufficient evidence, it had to be assumed that there would be no cost reduction effect
463 and that it was not cost-effective. Since these are all expected to improve further with the
464 accumulation of evidence, re-assessment of the cost-effectiveness of ophthalmologic screening
465 programs is needed in the future.

466 In conclusion, we evaluated the clinical effectiveness and cost-effectiveness of
467 ophthalmologic screening for AMD in adults using a Markov model based on real-world data
468 from Japan. The current study indicates that the screening program is highly effective in
469 preventing blindness (clinically effective) but not cost-effective from a value-for-money
470 perspective. The early start and frequent conduction of the screening program might lead to
471 improvements in both perspectives.

472

473 **Acknowledgments:**

474 This study was supported by a grant (19FA1001 from the Ministry of Health, Labor and Welfare,

475 Japan.)

476 **Author contributions**

477 Data collection: HT, AY

478 Writing of the article: HT, AY, AK, MM

479 Critical revision of the article: YH, RK, RG, MY

480 Final approval of the article: HT, AY, YH, RK, AK, MM, RG, MY

References

1. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. *Invest Ophthalmol Vis Sci*. 1995;36:182-91.
2. Munoz B, West SK, Rubin GS, Schein OD, Quigley HA, Bressler SB et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. *Arch Ophthalmol*. 2000;118:819-25.
3. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC et al. Racial Differences in the Cause-Specific Prevalence of Blindness in East Baltimore. *New England Journal of Medicine*. 1991;325:1412-7.
4. Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. *Clin Experiment Ophthalmol*. 2000;28:268-73.
5. Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. *Arch Ophthalmol*. 2000;118:264-9.
6. Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. *Jpn J Ophthalmol*. 2019;63:26-33.
7. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. *N Engl J Med*. 2008;358:2606-17.
8. Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. *Progress in retinal and eye research*. 2020;100906.
9. Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). *Ophthalmology*. 2016;123:1269-77.
10. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JJ, Vemulakonda GA et al. Age-Related Macular Degeneration Preferred Practice Pattern(R). *Ophthalmology*. 2020;127:P1-P65.
11. Tamura H, Goto R, Akune Y, Hiratsuka Y, Hiragi S, Yamada M. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study. *PloS one*. 2015;10:e0133628.
12. Brynskov T, Munch IC, Larsen TM, Erngaard L, Sørensen TL. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. *Acta Ophthalmol*. 2020;98:132-8.
13. Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE et al. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration:

- The Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:1751-61.
14. Nishikawa K, Oishi A, Hata M, Miyake M, Ooto S, Yamashiro K et al. Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy. *Scientific reports*. 2019;9:3620.
15. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). *Ophthalmology*. 2013;120:2292-9.
16. Chandra S, Rasheed R, Menon D, Patrao N, Lamin A, Gurudas S et al. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration. *Eye*. 2020.
17. Brown GC, Brown MM, Rapuano S, Boyer D. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration. *Am J Ophthalmol*. 2020;218:225-41.
18. Carrasco J, Pietsch G-A, Nicolas M-P, Koerber C, Bennison C, Yoon J. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. *Advances in Therapy*. 2020;37:300-15.
19. Chan CKW, Gangwani RA, McGhee SM, Lian J, Wong DSH. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening. *Ophthalmology*. 2015;122:2278-85.
20. Ho R, Song LD, Choi JA, Jee D. The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea. *PloS one*. 2018;13:e0206690.
21. Khalid S, Akram MU, Hassan T, Jameel A, Khalil T. Automated Segmentation and Quantification of Drusen in Fundus and Optical Coherence Tomography Images for Detection of ARMD. *J Digit Imaging*. 2018;31:464-76.
22. Venhuizen FG, van Ginneken B, van Asten F, van Grinsven MJ, Fauser S, Hoyng CB et al. Automated staging of age-related macular degeneration using optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2017;58:2318-28.
23. Peng Y, Dharssi S, Chen Q, Keenan TD, Agron E, Wong WT et al. DeepSeeNet: A Deep Learning Model for Automated Classification of Patient-based Age-related Macular Degeneration Severity from Color Fundus Photographs. *Ophthalmology*. 2019;126:565-75.
24. Cheung R, Chun J, Sheidow T, Motolko M, Malvankar-Mehta MS. Diagnostic accuracy of current machine learning classifiers for age-related macular degeneration: a systematic review and meta-analysis. *Eye*. 2021.
25. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. *Eye*. 2005;19:935-44.

26. Sasaki M, Harada S, Kawasaki Y, Watanabe M, Ito H, Tanaka H et al. Gender-specific association of early age-related macular degeneration with systemic and genetic factors in a Japanese population. *Scientific reports*. 2018;8:1-8.
27. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355:1419-31.
28. Elshout M, Webers CA, van der Reis MI, de Jong-Hesse Y, Schouten JS. Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study. *BMC Ophthalmol*. 2017;17:120.
29. Uyama M, Takahashi K, Ida N, Miyashiro M, Ando A, Takahashi A et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. *Br J Ophthalmol*. 2000;84:1018-23.
30. Sasaki M, Kawasaki R, Uchida A, Koto T, Shinoda H, Tsubota K et al. Early signs of exudative age-related macular degeneration in Asians. *Optom Vis Sci*. 2014;91:849-53.
31. Nakata I, Yamashiro K, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study. *Am J Ophthalmol*. 2013;156:1002-9 e2.
32. Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. *Ophthalmology*. 2009;116:2135-40.
33. Ministry of Health, Labour and Welfare. Abridged Life Tables for Japan 2017. 2018. <https://www.mhlw.go.jp/english/database/db-hw/lifetb17/index.html>. Accessed 06/05 2020.
34. Takahashi K, Ogura Y, Ishibashi T, Shiraga F, Yuzawa M. [Treatment guidelines for age-related macular degeneration]. *Nippon Ganka Gakkai Zasshi*. 2012;116:1150-5.
35. Sasaki M, Shinoda H, Koto T, Uchida A, Tsubota K, Ozawa Y. Use of micronutrient supplement for preventing advanced age-related macular degeneration in Japan. *Arch Ophthalmol*. 2012;130:254-5.
36. Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol*. 2001;119:1417-36.
37. Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. *Eye*. 2013;27:787-94.
38. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. *Ophthalmology*. 2012;119:1609-14.
39. Holden BA, Fricke TR, Ho SM, Wong R, Schlenther G, Cronje S et al. Global vision impairment due to uncorrected presbyopia. *Arch Ophthalmol*. 2008;126:1731-9.
40. Ministry of Health, Labour and Welfare. Consultation rate of specific medical checkups in 2017. 2019. https://www.mhlw.go.jp/stf/houdou/0000173038_00004.html. Accessed 06/05 2020.

41. e-Stat(Japanese Government Statistics). Population estimates at Oct 1, 2017. 2018. <https://www.e-stat.go.jp/dbview?sid=0003215841>. Accessed 06/05 2020.
42. Yanagi Y, Ueta T, Obata R, Iriyama A, Fukuda T, Hashimoto H. Utility values in Japanese patients with exudative age-related macular degeneration. *Jpn J Ophthalmol*. 2011;55:35-8.
43. Varma R, Wu J, Chong K, Azen SP, Hays RD, Los Angeles Latino Eye Study G. Impact of severity and bilaterality of visual impairment on health-related quality of life. *Ophthalmology*. 2006;113:1846-53.
44. Bank of Japan. Standard Forex Market. 2020. https://www.boj.or.jp/about/services/tame/tame_rate/kijun/kiju2011.htm/.
45. Research team on cost-effectiveness evaluation. Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council. Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H). 2019. https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf. Accessed 12/12 2020.
46. Shiroya T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? *Health economics*. 2010;19:422-37.
47. Ministry of Health, Labour and Welfare. 5th NDB open data 2021. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177221_00008.html. Accessed 07/10 2021.
48. Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H et al. RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study. *Retina*. 2020;40:1673-85.
49. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. *Ophthalmology*. 2012;119:1175-83.
50. Rim TH, Cheng CY, Kim DW, Kim SS, Wong TY. A nationwide cohort study of cigarette smoking and risk of neovascular age-related macular degeneration in East Asian men. *Br J Ophthalmol*. 2017;101:1367-73.
51. Yang JJ, Yu D, Wen W, Shu XO, Saito E, Rahman S et al. Tobacco Smoking and Mortality in Asia: A Pooled Meta-analysis. *JAMA Netw Open*. 2019;2:e191474.
52. Nakamura M. The point of guidance on smoking cessation. 2008. <https://www.niph.go.jp/soshiki/jinzai/koroshoshiryo/tokutei20/program/6-3.pdf>. Accessed 07/10 2021.
53. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. *Am J Ophthalmol*. 2012;153:209-13 e2.
54. Kawasaki R, Wang JJ, Ji GJ, Taylor B, Oizumi T, Daimon M et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. *Ophthalmology*. 2008;115:1376-81, 81 e1-2.

55. Obata R, Yanagi Y, Inoue T, Yasuda M, Oshima Y, Sawaguchi S et al. Prevalence and factors associated with age-related macular degeneration in a southwestern island population of Japan: the Kumejima Study. *Br J Ophthalmol*. 2018;102:1047-53.
56. Wolff J, Pauling J, Keck A, Baumbach J. The Economic Impact of Artificial Intelligence in Health Care: Systematic Review. *J Med Internet Res*. 2020;22:e16866.
57. Hiratsuka Y, Yokoyama T, Yamada M. Higher participation rate for specific health checkups concerning simultaneous ophthalmic checkups. *J Epidemiol*. 2020;advpub.
58. Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. *N Engl J Med*. 1997;337:1052-7.
59. Hayashida K, Imanaka Y, Murakami G, Takahashi Y, Nagai M, Kuriyama S et al. Difference in lifetime medical expenditures between male smokers and non-smokers. *Health Policy*. 2010;94:84-9.

633 **Tables**

634 **Table 1. Parameter values used in the Markov model with ranges used for univariate**
 635 **sensitivity analysis.**

Model parameters group	Model parameters	Classification	Base-case value	Range for univariate sensitivity analysis	References
Probability of initial state	Aged 40 years	Normal	96.15%	-	[26]
		Unilateral early AMD	3.85%	±50%	[26]
	Age to terminate model		90 years	-	
	Age to start screening		40 years	40, 50, 60, 70 years	
	Age to end screening		74 years	60, 70, 80, 90 years	
	Interval between screenings		5 years	1–10 years	
	Transition probabilities	Normal →early AMD	Age 40 years	0.181%	±50%
		Age 55 years	0.422%	±50%	[26]
Early AMD → moderate AMD		Age 40 years	0.50%	±50%	
		Age 50 years	0.50%	±50%	[32]
Early AMD → moderate AMD (second eye)			5.36%	±50%	[30]
Moderate AMD → severe AMD			76.92%	±50%	[28]
Severe AMD → blindness			18.52%	±50%	[28]
Epidemiology		Mortality rate		Census of 2017	
	Rates in screening				

Participation rate for Screening				
	Screening	50.00%	30.00%–100.00%	[40]
	Detailed examination	60.00%	30.00%–100.00%	
	Occasional (irregular) screening	20.00%	10.00%–50.00%	
Incidence rate of presbyopia		3.00%	±50%	[39]
Prevalence of presbyopia	Early/ Late AMD	20.00%	-	
		20.00% (in year 1 of stage change)	20.00% (between years 1 and 3 of stage change)	
	Severe AMD			
Consultation rate due to subjective severity	Severe AMD → blindness	100.00%	-	
Detection rate in screening				
	Sensitivity	80%	60%–100%	
	Specificity	95%	80%–100%	
Utility				
	better eye/worse eye			
Normal	Normal/normal	1.00	-	
	Normal/early	1.00	-	
	Normal/moderate	0.8265	-	
	Normal/severe	0.79675	-	
	Normal/blindness	0.767	-	
Prodromal	Early/early	0.97	±30%	
	Early/moderate	0.8115	-	
	Early/severe	0.78175	-	
	Early/blindness	0.752	-	
Moderate AMD	Moderate/moderate	0.653	±30%	[42]
	Moderate/severe	0.62325	-	
	Moderate/blindness	0.5935	-	
Severe AMD	Sever/severe	0.5935	±30%	[42]
	Sever/blindness	0.56375	-	
Blindness	Blindness/blindness	0.534	±30%	[42]

Cost				
	Screening	2,000 JPY	±50%	
	Detailed examination	14,160 JPY	±50%	*
	Observation: periodical examination	5,660 JPY	±50%	**
	Supplements (1 year)	54,432 JPY	±50%	
	Aflibercept (each time for one eye)	137,292 JPY	±50%	
	Endophthalmitis	1,052,750 JPY	±50%	
Discount rate		2.00%	0.00%–4.00%	[45]
Treatments (noninvasive)				
	For prodromal (supplements)			
	Intake rate	56.6%	25%–100%	[35]
	Rate of continuation of supplement intake each year	90%	50%–100%	
	Rate of suppression of AMD	25%	±50%	[36]
	Number of observations per year	4	2–6	
	For Blindness (only observation)			
	Number of observations per year	12	6–12	

636 AMD (age-related macular degeneration)

637 *The detailed examination cost was calculated by summing the following fee schedules in
638 Japanese social health insurance as of 2020: initial consultation (A000), slit lamp examination
639 (D257), fundus examination (D255), visual acuity tests (D263), refraction tests (D261),
640 measurement of corneal radius of curvature (D265), measurement of intraocular pressure

(D264), optical coherence tomography (D256-2), and fluorescein fundus angiography (D256-2).

**The observation cost was calculated by summing the following fee schedules in Japanese social health insurance as of 2020: subsequent consultation (A001), slit lamp examination (D257), fundus examination (D255), visual acuity tests (D263), and optical coherence tomography (D256-2).

Table 2. Parameter values regarding treatments used in the Markov model with ranges used for univariate sensitivity analysis.

Model parameters	Classification	Base-case value	Range for univariate sensitivity analysis	References
Number of observations per year		12	6–12	
Proportion of Aflibercept as initial treatment		100%		
Number of injections per year	1 st year	7	3-12	
	After 2 nd year	3	1–5	[14]
Positive state transition during treatment	Severe AMD → moderate AMD	21.9%	±50%	[14]
Negative state transition during treatment	Moderate AMD → severe AMD	1.40%	±50%	[14]
	Severe AMD → blindness	1.40%	±50%	[14]
State transition to stable state	1 st year	0%	±50%	
	After 2 nd year	20%	±50%	[14]
Sensor before treatment	Moderate/severe AMD	5%	±50%	
Sensor during treatment	Moderate/severe AMD	0%		
Incident rate of Endophthalmitis		0.03%	±50%	[38]

per injection

650 AMD (age-related macular degeneration)

651

652 **Table 3. Base-case cost-utility analysis in a simulated population**

	With screening	Without screening	Difference between ‘with screening’ and ‘without screening’
Number of blindness in 500,000 simulated cohort	48	81	33
Proportion of prevented blindness	-	-	40.7%
Number of people detected to have late AMD	14,329	14,600	271
Number of people detected to have AMD	64,305	19,198	45,107
Detected in screening	51,063	-	51,063
Detected in coincidental consultation	7,237	10,704	3,467
Detected in spontaneous consultation due to subjective severity	6,005	8,494	2,489
Duration of blindness [years]	7.3	9.9	2.6
Cost per person [JPY]	118,063	54,761	63,303
QALY per person	28.3734	28.3670	0.0064
ICER [JPY/QALY]	-	-	9,846,411

653 AMD (age-related macular degeneration); QALY (quality-adjusted life year); ICER (incremental cost-effectiveness ratio)

654

655 **Figure Legends**

656 **Fig. 1. Basic concepts of state transition in Markov models for AMD**

657 In the current study, age-related macular degeneration (AMD) was assumed to develop from a
658 normal eye via early to late AMD. Late AMD is categorized into three stages: moderate AMD,
659 severe AMD, and blindness. All patients were assumed to die equally according to the mortality
660 rate of their age from any state. In the stable state, no additional injections with aflibercept were
661 assumed. In each cycle, evaluated annually, each patient's disease condition was rated as
662 aggravated, maintained, or improved using transition probabilities, according to the reported
663 real-world data in Japan.

664

665 **Fig. 2. Tornado diagram showing one-way sensitivity analysis targeting cost-effectiveness**
666 **of the ophthalmologic screening program for AMD as the outcome.**

667 The top 10 most influential parameters among all 40 parameters in the one-way sensitivity
668 analysis are shown. The most influential parameter in the model was the utility value of the
669 blindness state, and the 2nd most influential parameter was the utility value of moderate late
670 AMD, where utility values were found to have a significant impact on the model.

671

672 **Fig. 3. The transition in the proportion of blindness from age-related macular**

673 **degeneration, by age.**

674 The transition of in proportion blindness in the screening and non-screening groups with and
675 without supplementation treatment are described. Screening interventions reduced the
676 proportion of blindness by 40.7%. The reduction effect of blindness was 56.9% after controlling
677 for age.

[Online Resource 1](#)

Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI

Supplementary Tables

Supplementary Table 1. Results of the scenario analysis for screening sensitivity and specificity with optical coherence tomography or artificial intelligence.

	Blindness prevention proportion [%]	ICER [JPY/QALY]
The base-case: fundus photographs interpreted by ophthalmologist	40.7	9,846,411
With OCT interpreted by ophthalmologist	43.2	10,483,508
Fundus photographs interpreted with AI	34.6	10,524,003
With OCT interpreted by AI	40.7	10,213,863

QALY (quality-adjusted life year), ICER (incremental cost-effectiveness ratio), OCT (optical coherence tomography), AI (artificial intelligence)

Supplementary Table 2. Results of scenario analysis in smoking cessation after AMD detection.

Proportion of smoking cessation in smokers after AMD detection	Blindness prevention proportion [%]	ICER [JPY/QALY]	Inhibition of late AMD development [%]	Delay in late AMD development [years]
The base-case:0%	40.7	9,846,411	1.9	0.19
10% of smokers	42.0	8,281,963	2.4	0.24

20% of smokers	41.6	6,012,733	2.8	0.23
30% of smokers	41.6	4,655,601	3.0	0.24

AMD (age-related macular degeneration); QALY (quality-adjusted life year); ICER (incremental cost-effectiveness ratio),

Supplementary Table 3. Results of scenario analysis in ophthalmologic screening schedule and cycle.

	Blindness prevention proportion [%]	ICER [JPY/QALY]	Age to start screening [y.o.]	Age to end screening [y.o.]	Interval between screening [years]
The base-case	40.7	9,846,411	40	74	5
The highest blindness prevention proportion	81.5	11,622,009	40	90	1
The lowest blindness prevention proportion	-1.2	5,653,116	40	50	7
The highest ICER	27.2	18,051,627	70	90	1
The lowest ICER	3.7	5,368,641	40	50	9

QALY (quality-adjusted life year); ICER (incremental cost-effectiveness ratio)